Phosphorothioate backbone modification modulates macrophage activation by CpG DNA

被引:108
作者
Sester, DP
Naik, S
Beasley, SJ
Hume, DA
Stacey, KJ [1 ]
机构
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia
[2] Univ Queensland, Dept Microbiol, Brisbane, Qld 4072, Australia
[3] Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia
关键词
D O I
10.4049/jimmunol.165.8.4165
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Macrophages respond to unmethylated CpG motifs present in nonmammalian DNA, Stabilized phosphorothioate-modified oligodeoxynucleotides (PS-ODN) containing CpG motifs form the basis of immunotherapeutic agents. In this study, we show that PS-ODN do not perfectly mimic native DNA in activation of macrophages. CpG-containing PS-ODN were active at 10- to 100-fold lower concentrations than corresponding phosphodiester ODN in maintenance of cell viability in the absence of CSF-1, in induction of NO production, and in activation of the IL-12 promoter. These enhancing effects are attributable to both increased stability and rate of uptake of the PS-ODN, By contrast, PS-ODN were almost inactive in down-modulation of the CSF-1R from primary macrophages and activation of the HIV-1 LTR, Delayed or poor activation of signaling components may contribute to this, as PS-ODN were slower and less effective at inducing phosphorylation of the extracellular signal-related kinases 1 and 2. In addition, at high concentrations, non-CpG PS-ODN specifically inhibited responses to CpG DNA, whereas nonstimulatory phosphodiester ODN had no such effect. Although nonstimulatory PS-ODN caused some inhibition of ODN uptake, this did not adequately explain the levels of inhibition of activity. The results demonstrate that the phosphorothioate backbone has both enhancing and inhibitory effects on macrophage responses to CPG DNA.
引用
收藏
页码:4165 / 4173
页数:9
相关论文
共 50 条
[1]   PHARMACOKINETICS OF ANTISENSE OLIGONUCLEOTIDES [J].
AGRAWAL, S ;
TEMSAMANI, J ;
GALBRAITH, W ;
TANG, JY .
CLINICAL PHARMACOKINETICS, 1995, 28 (01) :7-16
[2]   BINDING, UPTAKE, AND INTRACELLULAR TRAFFICKING OF PHOSPHOROTHIOATE-MODIFIED OLIGODEOXYNUCLEOTIDES [J].
BELTINGER, C ;
SARAGOVI, HU ;
SMITH, RM ;
LESAUTEUR, L ;
SHAH, N ;
DEDIONISIO, L ;
CHRISTENSEN, L ;
RAIBLE, A ;
JARETT, L ;
GEWIRTZ, AM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1814-1823
[3]   Mac-1 (CDllb/CD18) is an oligodeoxynucleotide-binding protein [J].
Benimetskaya, L ;
Loike, JD ;
Khaled, Z ;
Loike, G ;
Silverstein, SC ;
Cao, L ;
Khoury, JE ;
Cai, TQ ;
Stein, CA .
NATURE MEDICINE, 1997, 3 (04) :414-420
[4]  
Bennett R M, 1993, Antisense Res Dev, V3, P235
[5]   Characterization and modulation of immune stimulation by modified oligonucleotides [J].
Boggs, RT ;
McGraw, K ;
Condon, T ;
Flournoy, S ;
Villiet, P ;
Bennett, CF ;
Monia, BP .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1997, 7 (05) :461-471
[6]   IMMUNE STIMULATION BY AN ANTISENSE OLIGOMER COMPLEMENTARY TO THE REV GENE OF HIV-1 [J].
BRANDA, RF ;
MOORE, AL ;
MATHEWS, L ;
MCCORMACK, JJ ;
ZON, G .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (10) :2037-2043
[7]  
Broide D, 1998, J IMMUNOL, V161, P7054
[8]   CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[9]  
Cowdery JS, 1999, J IMMUNOL, V162, P6770
[10]  
Davis HL, 1998, J IMMUNOL, V160, P870